{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:19:09Z","timestamp":1787509149492,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K02406"],"award-info":[{"award-number":["24K02406"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005946","name":"Hokkaido University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP16lm0103004"],"award-info":[{"award-number":["JP16lm0103004"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.radonc.2025.111307","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:00:23Z","timestamp":1764172823000},"page":"111307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Long-term outcomes of concurrent chemo-proton therapy for unresectable stage III non-small cell lung cancer: a Japanese national registry study"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9809-9800","authenticated-orcid":false,"given":"Hiromitsu","family":"Iwata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3093-0386","authenticated-orcid":false,"given":"Kazushi","family":"Maruo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4431-8892","authenticated-orcid":false,"given":"Masaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4037-1688","authenticated-orcid":false,"given":"Takahiro","family":"Waki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3329-5999","authenticated-orcid":false,"given":"Masatoshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2348-4071","authenticated-orcid":false,"given":"Hiroshi","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-5162","authenticated-orcid":false,"given":"Kazuya","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Araya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Tatebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyako","family":"Satouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5276-3665","authenticated-orcid":false,"given":"Takayuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6450-3027","authenticated-orcid":false,"given":"Hideyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111307_b0005","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.21037\/tlcr-20-1210","article-title":"Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists","volume":"10","author":"Glatzer","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.radonc.2025.111307_b0010","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1200\/JCO.2002.03.055","article-title":"Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019","volume":"20","author":"Albain","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13014-019-1239-7","article-title":"Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis","volume":"14","author":"Liu","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0020","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0025","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2032","article-title":"Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non-small cell lung cancer: final results of a phase 2 study","volume":"3","author":"Chang","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0035","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijrobp.2016.10.001","article-title":"National cancer database analysis of proton versus photon radiation therapy in non-small cell lung cancer","volume":"97","author":"Higgins","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111307_b0040","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.ijrobp.2020.11.035","article-title":"Concurrent chemo-proton therapy using adaptive planning for unresectable stage 3 non-small cell lung cancer: a phase 2 study","volume":"109","author":"Iwata","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111307_b0045","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2017.74.0720","article-title":"Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer","volume":"36","author":"Liao","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0050","doi-asserted-by":"crossref","first-page":"i8","DOI":"10.1093\/jrr\/rrad017","article-title":"Clinical results of proton beam radiotherapy for inoperable stage III non-small cell lung cancer: a Japanese national registry study","volume":"64S","author":"Tatebe","year":"2023","journal-title":"J Radiat Res"},{"key":"10.1016\/j.radonc.2025.111307_b0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000531376","article-title":"Proton beam therapy for intrahepatic cholangiocarcinoma: a multicenter prospective registry study in Japan","volume":"13","author":"Mizumoto","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.radonc.2025.111307_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110868","article-title":"Clinical outcomes of proton beam therapy for inoperable stage I-IIA non-small cell lung cancer: Japanese nationwide registry study","volume":"207","author":"Nakamura","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110385","article-title":"Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry","volume":"198","author":"Harada","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0070","unstructured":"Proton Guideline JASTRO 7_13_2017-2.xlsx. Available from: https:\/\/www.jastro.or.jp\/en\/news\/proton_guideline_jastro_7_13_2017-2_cmarkandwatermark.pdf. Accessed March 1, 2025."},{"key":"10.1016\/j.radonc.2025.111307_b0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijrobp.2016.01.017","article-title":"Spot scanning and passive scattering proton therapy: relative biological effectiveness and oxygen enhancement ratio in cultured cells","volume":"95","author":"Iwata","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111307_b0080","unstructured":"Sjoberg DD, Baillie M, Fruechtenicht C, Haesendonckx S, Treis T. ggsurvfit: flexible time-to-event figures. R package version 1.1.0. 2024. https:\/\/CRAN.R-project.org\/package=ggsurvfit."},{"key":"10.1016\/j.radonc.2025.111307_b0085","unstructured":"Therneau T. A package for survival analysis in R. R package version 3.7-0. 2024. https:\/\/CRAN.R-project.org\/package=survival."},{"key":"10.1016\/j.radonc.2025.111307_b0090","unstructured":"Sjoberg DD, Fei T. tidycmprsk: competing risks estimation. R package version 1.1.0. 2024. https:\/\/CRAN.R-project.org\/package=tidycmprsk."},{"key":"10.1016\/j.radonc.2025.111307_b0095","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.3390\/cancers13143497","article-title":"Clinical outcomes of pencil beam scanning proton therapy in locally advanced non-small cell lung cancer: propensity score analysis","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111307_b0100","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.adro.2020.03.001","article-title":"Scanning beam proton therapy versus photon IMRT for stage III lung cancer: comparison of dosimetry, toxicity, and outcomes","volume":"5","author":"Zou","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0105","article-title":"Intensity-modulated radiotherapy for locally advanced lung cancer in the immunotherapy era: a prospective study WJOG12019L","volume":"6","author":"Harada","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.radonc.2025.111307_b0110","article-title":"Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.radonc.2025.111307_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.851032","article-title":"A systematic review of the mechanisms involved in immune checkpoint inhibitors cardiotoxicity and challenges to improve clinical safety","volume":"10","author":"Rubio-Infante","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.radonc.2025.111307_b0120","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/cncr.35230","article-title":"Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era","volume":"130","author":"Iocolano","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.111307_b0125","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/j.prro.2024.06.007","article-title":"A pilot trial of proton-cased cardiac sparing accelerated fractionated radiation therapy in unresectable non-small cell lung cancer with extended durvalumab therapy (PARTICLE-D)","volume":"14","author":"Bruno","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110019","article-title":"Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy","volume":"190","author":"Cortiula","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0135","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1667\/RR13500.1","article-title":"The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation","volume":"182","author":"Demaria","year":"2014","journal-title":"Radiat Res"},{"key":"10.1016\/j.radonc.2025.111307_b0140","doi-asserted-by":"crossref","first-page":"13444","DOI":"10.1038\/s41598-021-92942-1","article-title":"Impact of proton therapy on antitumor immune response","volume":"11","author":"Mirjolet","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2025.111307_b0145","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/2326-6066.CIR-17-0040","article-title":"Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment","volume":"5","author":"Muroyama","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.radonc.2025.111307_b0150","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1016\/j.ijrobp.2021.07.1245","article-title":"Immune-related radiation pneumonitis in patients undergoing durvalumab treatment after concurrent chemo-proton therapy","volume":"111S","author":"Iwata","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111307_b0155","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.lungcan.2021.12.005","article-title":"Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study","volume":"165","author":"Murakami","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2025.111307_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.874022","article-title":"Treatment patterns for patients with unresected stage III NSCLC: analysis of the surveillance, epidemiology, and end results (SEER) database","volume":"12","author":"Shang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0165","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1200\/JCO.2018.78.3134","article-title":"Future of protons depends on precision","volume":"36","author":"Liao","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0170","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14338\/IJPT\/18-00029.1","article-title":"Trends and outcomes of proton radiation therapy use for non-small cell lung cancer","volume":"5","author":"Moreno","year":"2018","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.radonc.2025.111307_b0175","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1002\/mp.16625","article-title":"An optimized framework for cone-beam computed tomography-based online evaluation for proton therapy","volume":"50","author":"Chang","year":"2023","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2025.111307_b0180","doi-asserted-by":"crossref","unstructured":"Paganetti H, Botas P, Sharp GC, Winey B. Adaptive proton therapy. Phys Med Biol 2021;66:10.1088\/1361-6560\/ac344f.","DOI":"10.1088\/1361-6560\/ac344f"},{"key":"10.1016\/j.radonc.2025.111307_b0185","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijrobp.2017.05.014","article-title":"Consensus guidelines for implementing pencil-beam scanning proton therapy for thoracic malignancies on behalf of the PTCOG thoracic and lymphoma subcommittee","volume":"99","author":"Chang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111307_b0190","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/j.cllc.2022.07.017","article-title":"Cardiopulmonary toxicity following intensity-modulated proton therapy (IMPT) versus intensity-modulated radiation therapy (IMRT) for stage III non-small cell lung cancer","volume":"23","author":"Yu","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2025.111307_b0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13014-016-0640-8","article-title":"Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC","volume":"11","author":"Giaddui","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0200","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/cncr.24998","article-title":"High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer","volume":"116","author":"Iwata","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.111307_b0205","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3390\/cancers15030887","article-title":"Comparison of recurrence patterns between adenocarcinoma and squamous cell carcinoma after stereotactic body radiotherapy for early-stage lung cancer","volume":"15","author":"Kita","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111307_b0210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(24)00573-4","article-title":"Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial","volume":"26","author":"Heinzerling","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111307_b0215","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jtho.2024.01.012","article-title":"Consolidation osimertinib versus durvalumab versus observation after concurrent chemoradiation in unresectable EGFR-mutant NSCLC: a multicenter retrospective cohort study","volume":"19","author":"Nassar","year":"2024","journal-title":"J Thorac Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025053113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025053113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:32:55Z","timestamp":1786537975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025053113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":43,"alternative-id":["S0167814025053113"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111307","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes of concurrent chemo-proton therapy for unresectable stage III non-small cell lung cancer: a Japanese national registry study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111307"}}